3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
32
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Ovarian Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Solid Tumors
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Solid Tumor
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms by Histologic Type
2
Leukemia, Myelomonocytic, Chronic
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
Temozolomide
156
Bevacizumab
69
Radiotherapy
61
Magnetic Resonance Spectroscopy
59
Irinotecan
31
Surgical Procedures, Operative
23
Radiation
23
Carboplatin
23
Specimen Handling
20
Carmustine
20
Nivolumab
19
Biopsy
17
Lomustine
16
Aminolevulinic Acid
15
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
pembrolizumab
12
Radiosurgery
12
Erlotinib Hydrochloride
12
fluorodopa F 18
11
Topotecan
11
Everolimus
11
Blood Specimen Collection
11
X-Rays
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
ribociclib
8
poly ICLC
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Glioma
×
cobimetinib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled